1. Home
  2. FENG vs GRFS Comparison

FENG vs GRFS Comparison

Compare FENG & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phoenix New Media Limited

FENG

Phoenix New Media Limited

HOLD

Current Price

$2.03

Market Cap

32.7M

Sector

Industrials

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$9.20

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FENG
GRFS
Founded
1998
1940
Country
China
Spain
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.7M
6.0B
IPO Year
2011
2006

Fundamental Metrics

Financial Performance
Metric
FENG
GRFS
Price
$2.03
$9.20
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
$10.15
AVG Volume (30 Days)
2.5K
538.7K
Earning Date
11-12-2025
01-01-0001
Dividend Yield
N/A
1.55%
EPS Growth
N/A
N/A
EPS
N/A
0.64
Revenue
$106,947,410.00
$8,821,017,248.00
Revenue This Year
N/A
$5.46
Revenue Next Year
N/A
$5.60
P/E Ratio
N/A
$17.68
Revenue Growth
9.17
7.31
52 Week Low
$1.28
$6.19
52 Week High
$3.65
$11.14

Technical Indicators

Market Signals
Indicator
FENG
GRFS
Relative Strength Index (RSI) 39.94 57.67
Support Level $2.01 $8.81
Resistance Level $2.08 $9.22
Average True Range (ATR) 0.04 0.26
MACD 0.01 0.08
Stochastic Oscillator 13.33 95.25

Price Performance

Historical Comparison
FENG
GRFS

About FENG Phoenix New Media Limited

Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives revenue from China.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: